1. Corporative analysis of cytotoxisity of anticancer drugs: preliminary studies with L-OHP. ICIG, Internal Report, March 23, 1990.   
2. Woynarowski J, Chapman W, Napier C et al. Sequence- and region-specificity of oxaliplatin adducts in naked cellular DNA. Mol. Pharmacol. 1998. V. 54: 770–7.  
3. Saris C, Van Der Vart P, Rietbroek R et al. In vitro formation of DNA adducts by cisplatin, loboplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis 1996; 17: 2763–69.     
4. Kidani Y, Nojo M, Tashiro T. Antitumor activity of Platinun (II) Complexes of 1,2-diaminocyclohexane isomer. Gann 1980; 71: 637–43.
5. Dixe O, Ortuzar W, Alvarez M et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 1996; 52: 1855–65.  
6. Goodisman J, Hagrman D, Tasca K et al. Analysis of platinum compounds. Cancer Chemother Pharmacol 2006; 57: 257–67.       
7. Monti E, Gariboldi M, Maiocchi A et al. Cytotoxicity of cisplatinum (II) conjugate models. The effect of chelating arms and leaving groups on cytotoxicity: A quantitative structure-activity relationship approach. J Med Chen 2005; 48: 857–66.    
8. Bastian G et al. Report on the pharmacokinetics of oxaliplatin in patients with normal and impaired renal fusion. Debiopharm Internal Report. September, 1994.   
9. Pharmacokinetics of (1R,2R – diaminocyclohexane) oxaliplatin (II) in comparison with cisplatin following a single intravenous injection in rabbits. Cancer Chemoth. Pharmacol 1993; 31: 475–80.   
10. Gamelin K, Allain P. Pharmacokinetics behavior of oxaliplatin in repeated administration at 130 mg/m2 every three weeks.  Debiopharm Internal Report, October 15, 1995.
11. Руководство по химиотерапии опухолевых заболеваний под редакцией Переводчиковой Н.И. 2005; с 133.  
12. Лекарственная терапия опухолей. Под редакцией М.Л. Гершановича, В.А. Филова. 2006.  
13. Этюды по химиотерапии (пять лет спустя). Под редакцией В.А. Горбуновой. 2006; с 179–87.
14. В.Л. Винокуров. Рак яичников: закономерности метастазирования и выбор адекватного лечения больных. 2004; 293–307.
15. Периферический рак легкого: количественная оценка эффективности радикального химиолучевого лечения. Редакторы Р.В. Ставицкий, Г.А. Паньшин. 2008; 28–38. 
16. Адъювантная химиотерапия колоректального рака. Л.В. Манзюк.  Новые возможности лекарственного лечения  онкологических больных. Материалы школы по онкологии (химиотерапия опухолей). 16–20 апреля 2007 г. Москва. С. 20–34. 
17. Dunn T, Schmoll H, Grunwald V et al. Comporative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell line. Invect New Drugs 1997; 15: 109–14.  
18. Гарин А.М. , Базин И.С. . Десять наиболее распространенных злокачественных опухолей. 2006. 
19. Goldberg R, Sargent D, Morton R et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clinical Oncology 2004; 22: 23–30.  
20. Andre T, Boni C, Mounedji-Boundiaf L. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer, New Engl J Med 2004; 350: 2343–51. 
21. De Gramont et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I; 25: 18S.
22. Bleiberg H, de Granont A. Oxaliplatin + 5-fluorouracil experience in patients with advanced colorectal cancer. Sem. in Oncol 1998; 25(2): Suppl 5: 32–9. 
23. Giacchetti S, Perpoint B, Zidani R et al. Phase III multicenter randomized trail of oxaliplatin added to chronomodutated  fluauracil-leucovorin as first line treatment of metactatic colorectal cancer. JClin Oncol 2000; 18: 899–906.   
24. De Gramont A, Buyse M, Abrahantes J et al. Реиндукция оксалиплатина увеличивает продолжительность жизни при поздних стадиях колоректального рака. J Clin Oncol Т 1, (4) с 293–98. (Русское издание).
25. Cvitcovic E, Wasserman E, Goldwasser F et al. Preliminary report on oxaliplatin (L-OHP)/CPT-11 phase I trial in gastrointestinal malignancies: an active combination. Proc. ASCO. 1997; 16: 229a.  
26. Орлова Р.В. Лекарственное лечение опухолей желудочно-кишечного тракта. Практическая онкология, 2005; 6(1); 33–42.
27. Tournigand Ch, Louver Ch, Quinax E et al. FOLFIRI followed FOLFOX versus  FOLFOX followed by FOLFIRI in metastatic colorectal cancer: final results of a phase III study. Proc ASCO 2001; 20.  Abstr. 494.  
28. Comella P, Vessida B, Palmeri S et al. Biweekly oxaliplatin with oral capecitabin (OXXEL regimen)  at first line treatment of metastatic colorectal cancer patients. A Southern Italy Cooperative Oncology Group phase II study. Cancer Chemother. And Pharmacol 2005; 56(2): 481–6.  
29. Comella P, Massida B, Filippelli G et al. Capecitabin or Folinic acid/ Fluorouracil i.v. bolus plus Eloxatin evaluation (COFFE trial) in metastatic colorectal carcinoma (MCRC): final results of the Southern Italy Cooperative Oncology Group(SICOG) phase III trial 0401, Proc. ECCO 2007; 5(4): Absr.3044.
30. Twelwes C. Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer? Oncology 2002; 16(12): Suppl. 23–6.  
31. Goldberg R, Sargent D, Morton R et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combination in patients with previously untreated metastatic colorectal cancer. J Clin Oncolog 2004; 22: 23–30. 
32. Grothey А, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with available of fluorouracil, irinotecan and oxaliplatin regardless of whether doublet or single agent therapy is used first line. J Clin Oncol 2005; 23: 9441–2.
33. Falcone A, Ricci S, Brunetti I et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007; 25(13):1670–6.
34. Masi G, Bursi S, Loupakis F et al. Long-term outcome of unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line FOLFOXIRI followed by R0 surgical resection of metastases. ECCO 2007; 5(4): Abstr. 3022
35. Bursi S, Masi G, Loupakis F et al. Capecitabin(C), in combination with irinotecan (I) and oxaliplatin(O) (XELOXIRI) as first-line treatment of metastatic colorectal cancer(MCRC): results of a pilot study by the Gruppo Oncologico Nord Ovest. ECCO 2007: 5(4): Abstr. 3063
36. Bismuch H. 2004. Цит. по:  Горбунова В.А., Топчиева С.В. Оксалиплатин – новые возможности химиотерапии солидных опухолей. Укр. Мед. Часопис. 2004; 3: 81–6.
37. Nordlinger B et al. Randomized study of perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for respectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983). In press The Lancet 3.22.08.
38. Heinemann V, Hinke A, Bock S et al. Gemcitabine-based combinations (gem+x) vs gemcitabine (gem) alone in the treatment of CRC: a analysis of sixteen randomized trials. ASCO 2007; Abstr. 4515.
39. Bendell JC, George D, Nixon A et al. Results of a phase I study of bevacizumab (BV), everolimus (EV), and erlotinib (E) in patients with advanced solid tumors. 3548
40. Hochster H et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer(mCRC): final analysis of the TREE-study. ASCO 2006; Abstr. 3510
41. Giantonio BJ. Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings. Semin Oncol 2006; 33 (5 Suppl. 10): S15–8.
42. Meyerhardt J. A phase II study of capecitabin, oxaliplatin and erlotinib in previously treated patients with metastatic colorectal cancer. Proc. ASCO 2004. V.23, Abstr. 3580. 
43. Venook A, Niedzwiecki D, Hollis D et al. Phase III study of irinotecan/5FU/LV(FOLFIRI) or oxaliplatin/5FU/LV(FOLFOX)±cetuximab for patients(pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. Proc. ASCO 2006; Abstr. 3509. 
44. Bokemeyer C, Staroslawska E, Makhson A et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX4) in the first-line treatment of metastatic colorectal cancer (mCRC): a large-scale phase II study, OPUS. Proc. ASCO 2007; Abstr. 3004
45. Zampino MG, Magni E, Zorzino L et al. Epidermal growth factor receptor (EGFR) serum level may predict response in patients with advanced colorectal cancer (ACC) treated with gefitinib. ASCO 2007; Abstr. 4119.
46. Steward W et al. 2004. Expanded phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor in combination wiyh FOLFOX4 as first line treatment for patients with metastatic colorectal cancer. Ann Oncol 2004; 23; Abstr. 3580. 
47. De Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or whithout oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938–47.
48. Grothey A, Sargent D, Goldberg R, Schmoll HJ. Survival of Patients With Advanced Colorectal Cancer Improves With the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of Treatment JCO 2004; 1209–14.

Э.К.Возный, А.Ю.Попов, Т.А.Астраханкина, Е.П.Гришуненкова, Е.В.Полянская

Городская клиническая больница №57, Москва